Law360, New York (June 11, 2007, 12:00 AM EDT) -- Trouble continues to mount for the biotechnology company Dendreon Corp. since it announced in May that the U.S. Food and Drug Administration asked for more information regarding its advanced prostate cancer drug, Provenge. At least three securities lawsuits have been filed, two coming in the last week.
One lawsuit, filed Wednesday in the U.S. District Court for the Western District of Washington, alleges that Washington-based Dendreon Corp. and some of its officers and directors were not forthcoming about the approval process for its drug.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.